Clinical Trials Browser

mirvetuximab soravtansine × Clear all

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Fallopian Tube Neoplasms, Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Endometrial Neoplasms

Ovarian Neoplasms

Endometrial Neoplasms

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Endometrial Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

GLORIOSA

TREVI-OC-01

PICCOLO

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

MIRASOL

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

MIROVA

Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

SORAYA

Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer

IMGN853-0401

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

FORWARD I

Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer

IMGN853